Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Intellia Therapeutics, with 9 buy, 9 hold, 4 sell and 1 strong-buy recommendations. The average 12-month price target is $20.19, compared with the stock’s recent opening price of $10.68.
• Intellia reported quarterly revenue of $15.05 million and an adjusted loss of $0.81 per share, beating analyst estimates of $13.81 million in revenue and a $0.92-per-share loss. Analysts expect a full-year loss of approximately $3.18 per share.
• Institutional investors and hedge funds own 88.77% of the company, while insiders own 3.50%; two executives recently sold shares, including one sale made to cover tax withholding on vested equity awards.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.1875.

A number of research analysts recently weighed in on the company. Citigroup reaffirmed a "market outperform" rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. Citizens Jmp reissued a "market outperform" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Wall Street Zen downgraded Intellia Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Finally, Robert W. Baird increased their target price on Intellia Therapeutics from $7.00 to $13.00 and gave the stock a "neutral" rating in a report on Monday, April 27th.

Intellia Therapeutics Stock Performance

NTLA opened at $10.68 on Monday. The company has a fifty day moving average price of $13.85 and a two-hundred day moving average price of $13.51. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25. The company has a market cap of $1.49 billion, a P/E ratio of -3.02 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million for the quarter, compared to analysts' expectations of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the prior year, the firm earned ($1.10) EPS. On average, research analysts forecast that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares of the company's stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. increased its holdings in Intellia Therapeutics by 38.0% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 220,523 shares of the company's stock worth $3,731,000 after purchasing an additional 60,720 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Intellia Therapeutics in the first quarter valued at approximately $404,000. Avidity Partners Management LP purchased a new position in shares of Intellia Therapeutics during the first quarter valued at approximately $962,000. Wellington Grp LLC boosted its position in shares of Intellia Therapeutics by 50.9% during the first quarter. Wellington Grp LLC now owns 46,297 shares of the company's stock valued at $594,000 after buying an additional 15,620 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Intellia Therapeutics by 11.2% during the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company's stock worth $17,713,000 after buying an additional 139,325 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.